New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
Ramsey Baghdadi
Ramsey Baghdadi covered regulation, reimbursement, and legislative policy for over a decade as Editor-in-Chief of The RPM Report and a contributing editor to Pink Sheet. He previously served as managing editor for the OTC drug and dietary supplement industry publication The Tan Sheet. Prior to his work in the drug sector, he covered the medical device industry as financial editor of The Gray Sheet.
Advertisement
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ramsey Baghdadi
Louisiana Purchase: State Eager To Test “Netflix Model” For Rx Spending
A subscription payment model could be a solution for high-priced drugs, Louisiana thinks – and appears to have at least one manufacturer willing to participate. Will the Trump Administration agree?
REDUCE-IT Will Test Risks Of Weakening Protection Of FDA-Labeled Claims
Amarin spent five years and lots of money to show Vascepa reduced the risk of cardiovascular events. REDUCE-IT trial results will test what Amarin will get for conducting the trial and whether the company’s off-label argument could work against them.
Medicare's CAR-T Panel Underscores Hurdles For PROs – And FDA/CMS Collaboration
MEDCAC meeting demonstrates complexity of patient-reported outcomes and place for PROs in regulatory decision-making compared to coverage.
Subsys Makes A Bad Impression On FDA REMS Panel Members
CMS and FDA data showed prescriptions jumping while other fentanyl products were coming down.
HHS Part B Plan Gets Pharma's Attention, But Savings Target May Be Too High
Regeneron analysis of policy's potential impact on Eylea signals that MA plans will face overwhelming challenge to achieve 20% savings in Part B.
The 'Dead Cat' Strikes Back: What Does US FDA Do With A Challenging Panel Outcome?
Akcea’s volanesorsen for familial chylomicronemia syndrome barely made it through advisory committee due to a rare but unpredictable and rapidly presenting adverse event that likely can’t be resolved with a REMS. Now what?
Advertisement